Key Points
- Leonard Reyno sold 10,000 CCCC shares on Jan. 16 at an average price of $2.22 for $22,200, reducing his stake by 6.01% to 156,382 shares (valued about $347,168).
- C4 Therapeutics opened at $2.24 with a market cap of $216.6M, a negative P/E of -1.34, a 12‑month range of $1.09–$4.03, and 50/200‑day moving averages near $2.32/$2.36.
- The stock has a consensus "Moderate Buy" analyst rating with a $7.25 target (6 Buys, 2 Holds, 1 Sell) and ~78.8% institutional ownership, with several funds recently increasing positions.
C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) insider Leonard Reyno sold 10,000 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $2.22, for a total transaction of $22,200.00. Following the transaction, the insider directly owned 156,382 shares of the company's stock, valued at $347,168.04. This trade represents a 6.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
C4 Therapeutics Trading Up 0.7%
Shares of CCCC stock opened at $2.24 on Friday. The stock has a market capitalization of $216.59 million, a price-to-earnings ratio of -1.34 and a beta of 2.93. C4 Therapeutics, Inc. has a 12-month low of $1.09 and a 12-month high of $4.03. The stock's 50-day moving average price is $2.32 and its 200-day moving average price is $2.36.
C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. The company had revenue of $11.23 million during the quarter, compared to analyst estimates of $6.28 million. C4 Therapeutics had a negative return on equity of 64.40% and a negative net margin of 395.51%. As a group, research analysts predict that C4 Therapeutics, Inc. will post -1.52 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of CCCC. Wasatch Advisors LP lifted its holdings in shares of C4 Therapeutics by 10.4% in the 2nd quarter. Wasatch Advisors LP now owns 7,424,662 shares of the company's stock worth $10,617,000 after acquiring an additional 700,253 shares during the last quarter. Vanguard Group Inc. grew its holdings in C4 Therapeutics by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 3,191,557 shares of the company's stock valued at $7,085,000 after purchasing an additional 173,535 shares during the last quarter. Bank of America Corp DE raised its position in C4 Therapeutics by 2.2% in the 3rd quarter. Bank of America Corp DE now owns 2,053,162 shares of the company's stock worth $4,558,000 after purchasing an additional 45,158 shares during the period. Two Sigma Investments LP lifted its stake in C4 Therapeutics by 22.1% in the third quarter. Two Sigma Investments LP now owns 834,726 shares of the company's stock worth $1,853,000 after purchasing an additional 151,127 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of C4 Therapeutics by 8.6% during the first quarter. Goldman Sachs Group Inc. now owns 622,720 shares of the company's stock valued at $996,000 after buying an additional 49,065 shares during the period. Institutional investors own 78.81% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on CCCC. Stephens restated an "overweight" rating and issued a $6.00 price target on shares of C4 Therapeutics in a research report on Monday, September 22nd. Cowen started coverage on shares of C4 Therapeutics in a research report on Tuesday, December 2nd. They set a "buy" rating for the company. TD Cowen assumed coverage on shares of C4 Therapeutics in a research note on Tuesday, December 2nd. They issued a "buy" rating for the company. Wells Fargo & Company upped their target price on shares of C4 Therapeutics from $5.00 to $10.00 and gave the company an "overweight" rating in a research report on Tuesday, September 23rd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of C4 Therapeutics in a report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $7.25.
Get Our Latest Report on C4 Therapeutics
About C4 Therapeutics
(
Get Free Report)
C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body's natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.
The company's pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
